Justification-Center for Biologics Evaluation and Research (CBER) Scientific Data Abstraction and Information Management
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA), specifically the Center for Biologics Evaluation and Research (CBER), has issued a Justification for a Sole Source Firm Fixed Price Purchase Order for Scientific Data Abstraction and Information Management. This action, pursuant to FAR 6.302-1 (Only One Responsible Source), explains the rationale for awarding the contract without full and open competition. The estimated value for this action is $2,001,241.20.
Purpose & Rationale
This "Justification for an Exception to Fair Opportunity" (JEFO) outlines the FDA's decision to award the contract to MPF-ZAI. The justification stems from MPF-ZAI's unique qualifications, including exclusive access to a proprietary database system, specialized methodologies, and training essential for CBER's scientific data abstraction needs. A prior pre-solicitation notice on SAM.gov did not yield any responses from other vendors capable of meeting the specific requirements.
Contract Details
- Type: Sole Source Firm Fixed Price Purchase Order
- Authority: FAR 6.302-1 (Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements)
- Estimated Value: $2,001,241.20
- Place of Performance: Silver Spring, MD, United States
- Published Date: May 19, 2026
Future Competition Commitment
The FDA is committed to promoting future competition for similar requirements. To achieve this, the agency plans to conduct thorough market research, engage in advance planning, and review requirements to ensure neutrality. These actions aim to remove barriers and foster a competitive environment for subsequent acquisitions.
Contact Information
- Primary: Natalie Brown (Natalie.Brown@fda.hhs.gov)
- Secondary: Ian Weiss (Ian.Weiss@fda.hhs.gov, 3017965728)